Biogen Inc and Japanese partner Eisai Co said on Thursday the U.S. Food and Drug Administration (FDA) had granted 'fast track' designation to their experimental therapy lecanemab for the treatment of early Alzheimer's disease.
said on Thursday the U.S. Food and Drug Administration had granted "fast track" designation to their experimental therapy lecanemab for the treatment of early Alzheimer's disease.The drug works in a similar manner to Biogen's Aduhelm and gets rid of sticky deposits of a protein called amyloid beta from brains of patients in the initial stages of the disease to mitigate its impact.
Biogen and Eisai have jointly developed three experimental drugs for the brain-wasting disease, which affects millions around the world. Adulhelm's development was nearly abandoned after disappointing trial results in 2019, but Biogen revived it after reviewing data that showed higher doses of the drug could slow disease progression.
Adulhelm, known scientifically as aducanumab, was dealt a setback in Japan on Wednesday when a health ministry panel said that inconsistent trial results made it difficult to determine its efficacy.Reporting by Vishal Vivek in Bengaluru, Rocky Swift in Tokyo; Editing by Vinay DwivediSubscribe for our daily curated newsletter to receive the latest exclusive Reuters coverage delivered to your inbox.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Biogen, Eisai Alzheimer's drug gets 'fast track' designation from FDABiogen Inc and Japanese partner Eisai Co said on Thursday the U.S. Food and Drug Administration (FDA) had granted 'fast track' designation to their experimental therapy, lecanemab, for the treatment of early Alzheimer's disease.
Lire la suite »
Biogen, Eisai Alzheimer's drug gets 'fast track' designation from FDABiogen Inc and Japanese partner Eisai Co said on Thursday the U.S. Food and Drug Administration (FDA) had granted 'fast track' designation to their experimental therapy, lecanemab, for the treatment of early Alzheimer's disease.
Lire la suite »
What’s Behind Biogen’s Move To Cut Prices On Its Controversial Alzheimer’s Drug Aduhelm?This week, drugmaker Biogen made a stunning announcement: It is going to cut in half the price of its controversial Alzheimer’s drug Aduhelm.
Lire la suite »
FDA clears second at-home Covid treatment, from MerckThe FDA's authorization of Merck's oral antiviral drug molnupiravir comes despite the agency's advisory committee expressing concerns about the safety and efficacy of the drug.
Lire la suite »
FDA authorizes Merck's COVID pill for some high-risk adultsThe Food and Drug Administration on Thursday authorized an antiviral pill developed by Merck and Ridgeback Biotherapeutics to treat some adults at high risk of becoming severely ill from COVID-19, despite concerns over its effectiveness and safety. Why it matters: Effective at-home antiviral drugs designed to prevent or treat COVID-19 could be key pandemic-fighting tools, especially as new variants emerge. Stay on top of the latest market trends and economic insights with Axios Markets. Subscrib
Lire la suite »